
Superpower peptides available for pre-order. Get first access.

Peptide science
Are peptides legal?
Peptide legality in the US depends on the route: FDA-approved drug, compounded by a licensed pharmacy, or research-only. Status as of November 2026.
Quick answer
Peptide legality in the US depends on the route, not the molecule. New FDA-approved peptide drugs typically complete Phase 1 to 3 trials, with Phase 3 enrolling 300 to 3,000 volunteers. Compounded peptides are not FDA-approved, and FDA does not verify their safety or quality. On October 30, 2026, HHS issued a non-binding draft policy covering six peptides at 503A pharmacies. Research-use-only peptides have no approval for human use.
- Published
- November 9, 2026
- Last updated
- November 9, 2026
Peptide legality depends on the regulatory route
Whether peptides are legal in the US depends on their regulatory route. Federal law treats FDA-approved peptide drugs, pharmacy-compounded peptides, and research-use-only peptides differently. No peptide class is legal or illegal as a whole, since one molecule can take several routes. This guide reflects federal policy as of November 2026.
| Route | Who makes it | FDA review before sale | Human use |
| FDA-approved peptide drug | A drug manufacturer | Yes, after Phase 1 to Phase 3 human trials1 | By prescription, with labeled indications, dosage, and warnings2 |
| Compounded by a 503A pharmacy | A state-licensed pharmacy | No; FDA does not verify safety, effectiveness, or quality3 | For an identified patient with a valid prescription4 |
| Compounded by a 503B outsourcing facility | An outsourcing facility held to manufacturing standards and FDA inspection5 | No | Patients, or clinics as office stock without a patient-specific prescription |
| Dietary supplement | A supplement maker | No drug approval; deemed to be a food6 | Must be intended for ingestion6 |
| Cosmetic | A cosmetic maker | No premarket approval, except for color additives7 | Cleansing or appearance claims7 |
| Research use only | Often foreign manufacturers8 | No | Not approved; little or no human safety information9 |
FDA-approved peptide drugs carry the most human testing of the six routes.
FDA-approved peptide drugs are reviewed before reaching patients
An FDA-approved peptide drug is legal to prescribe because it passed a review of its safety and efficacy10. Phase 3, the largest pre-approval stage, typically enrolls 300 to 3,000 volunteers1 over one to four years.
Approved peptide drugs, including GLP-1 receptor agonists, help manage diabetes, obesity, cancer, and rare diseases11.
Compounded and research copies inherit none of that trial evidence, since they skip FDA's review for safety and effectiveness12.
Compounded peptides can be legal without FDA approval
A licensed pharmacy can legally prepare a compounded peptide under federal compounding law5. Compounded drugs are not FDA-approved, so FDA does not verify their safety, effectiveness, or quality3 before sale.
A 503A pharmacy compounds for an identified patient with a valid prescription4. A 503B outsourcing facility, inspected by FDA5, can also supply clinics directly.
Peptides without a pharmacopeia standard or approved-drug status need a spot on the 503A bulks list13, FDA's still-developing roster of allowed raw ingredients.
Three federal steps reshaped peptide compounding in 2026:
- 1.April 2026: Nominations for several peptides were withdrawn14, removing them from Category 2, FDA's list of bulk substances that may pose significant safety risks9. The withdrawal alone approved no peptide and permitted no compounding8.
- 2.July 23 and 24, 2026: FDA's compounding advisory committee reviewed seven peptides for the bulks list15 and backed listing six14, against FDA staff advice.
- 3.October 30, 2026: HHS issued a draft enforcement-discretion policy16 for BPC-157, TB-500, KPV, MOTS-c, epitalon, and Semax. HHS does not intend to act against state-licensed 503A pharmacies compounding them by prescription with FDA-registered ingredient sources8, among other conditions.
The policy approves no peptide, adds none to the bulks list, and excludes 503B outsourcing facilities14. HHS may revisit the non-binding policy16, with comments due November 13, 2026.
FDA declared the semaglutide and tirzepatide shortages resolved by February 21, 202517. FDA's grace period for 503A pharmacies ran until March 2025 for tirzepatide17 and April 2025 for semaglutide17. Since then, 503A pharmacies may not regularly compound essentially a copy4 of either approved drug, unless a change makes a significant difference for an identified patient4. FDA has also warned of dosing errors with compounded semaglutide18, some followed by hospitalization.
Federal rules treat chains over 40 amino acids19 as proteins instead of peptides. Protein biologics cannot be compounded3.
Peptides also reach store shelves as supplements and skincare, under separate federal rules.
Peptide supplements and cosmetics follow different rules than drugs
Peptide supplements and cosmetics need no prescription, but a seller's claims7 can turn either one into a drug.
A dietary supplement must be intended for ingestion6, as oral collagen peptides are, so injectable peptides cannot qualify. Substances first approved or studied as new drugs6 are excluded too.
Cosmetics need no FDA approval before sale7, apart from color additives. A peptide skincare cream marketed to change how the body works is regulated as a drug.
Peptides labeled for research use only fit none of these routes.
Research-use-only peptides are not approved for human use
Research-use-only peptides have no FDA approval for any human use. Federal officials have called those from foreign manufacturers a safety risk to US patients8.
"For Research Use Only" is a federal labeling statement for diagnostic products still in laboratory research20.
Rigorous human safety data are scarce10 for unapproved peptides. In one review of BPC-157 in sports medicine, 35 of 36 studies were preclinical21, with no clinical safety data.
FDA's concerns include immune reactions9, peptide-related impurities, and poorly characterized active ingredients. Case reports also link melanotan II to serious harms, including melanoma9.
Poorly controlled synthesis can leave peptides with missing amino acids, oxidation, or unrelated peptides22. Falsified cysteine-containing peptide drugs from suspected illegal online pharmacies tested 5% to 75% pure23. Some samples held arsenic up to 10 times23 the injectable safety limit.
A research label verifies neither a product's contents nor any human testing, so the label says little about long-term safety.
Long-term safety data on peptides remain limited
One large outcome trial of approved semaglutide followed 17,604 adults for 39.8 months on average24, about 3.3 years. For unapproved peptides, rigorous human safety data remain scarce10.
Reports on compounded GLP-1 drugs cite preparation errors and contamination more often25 than reports on approved versions. FDA reviewers found insufficient clinical safety information26 on BPC-157 and no studies of its cancer risk.
Human testing behind a peptide tracks the same regulatory route that decides its legal status.
Where can I learn about peptides?
Peptide rules in the US shifted several times in 2026, from withdrawn nominations to a draft HHS policy. For anyone following those changes, Superpower’s peptide library is a dependable reference. Each guide is written and fact-checked by a team of health journalists and licensed clinicians.
One molecule can take several legal routes with an identical structure, and the science behind peptides explains what that structure is and how it acts.
IMPORTANT SAFETY INFORMATION
This article describes how US federal law treats peptides by regulatory route as of November 2026. It is general information, not legal or medical advice, and peptide status can change as HHS and FDA finalize pending policies.
FDA-approved peptide drugs are prescription medications whose FDA-approved labeling lists their indications, dosing, warnings, and side effects. Compounded medications are prepared by a licensed compounding pharmacy and are not FDA-approved. They have not been evaluated by the FDA for safety, efficacy, or quality in the same manner as commercially manufactured branded products. Compounded semaglutide and compounded tirzepatide may differ from the branded versions in formulation, concentration, and inactive ingredients.
Peptides labeled "for research use only" or "not for human consumption" are not approved for human use, and FDA has not reviewed them for human safety, effectiveness, or quality. Products bought through unregulated channels may contain incorrect doses, contaminants, or misidentified compounds. Superpower Health does not prescribe, sell, or facilitate access to peptide products labeled "for research use only" or "not for human consumption."
This content is not a substitute for medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting, changing, or stopping any peptide or prescription medication.
Prescribing information for FDA-approved drugs is available on DailyMed27. FDA's rules for compounding ingredients are on its page on bulk drug substances used in compounding13.